Abstracts tagged "Fatigue"

Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Zahi Touma¹, Christopher Saffore², Karim Masri³, Jerry Clewell³, Emily Goddard⁴, Grace O'Neill⁴, Madelane Foxall⁴ and Karen H. Costenbader⁵, ¹University of Toronto, Toronto, ON, Canada, ²AbbVie Inc., waukegan, IL, ³AbbVie Inc., North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…
Abstract Number: 1487 • ACR Convergence 2025
Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Jennifer Rogers¹, Amanda Eudy², Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Christie Clipper⁶, Ralph Snyderman⁷, Anna Batsakes⁶, Leigh Saner⁶, Dana Burshell³, Mithu Maheswaranathan⁴, Lisa Criscione-Schreiber⁴, Rebecca Sadun⁸, Nathaniel Harris⁵, Kai Sun⁸, Kelsey Dunn⁶, Jenny Herndon⁶, Vonne Jacobs⁶ and Megan Clowse⁹, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Duke University, Chapel Hill, NC
Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
Abstract Number: 1403 • ACR Convergence 2025
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
Anna Kuhn¹, Magdalena Seng², Björn Christian Frye³, Sebastian Fähndrich³, Lydia Vollmer³, Jacques-eric GOTTENBERG⁴, Florian Kollert⁵, Reinhard Voll⁶ and Stephanie Finzel⁷, ¹¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, Freiburg, Germany, ²¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; ²University Medical Center, Department of Radiology and Nuclear medicine, Basel, Switzerland, Freiburg, Germany, ³³University Medical Center, Department of Pulmonology, Freiburg, Germany, Freiburg, Germany, ⁴Hautepierre Hospital, STRASBOURG, Alsace, France, ⁵¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern; Switzerland Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶University Medical Center Freiburg, Freiburg, Germany, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Background/Purpose: About 70% of patients with primary Sjögren's disease (pSjD) suffer from fatigue. Fatigue is associated with functional deficits(1), leading to anxiety, depression and reduced…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…
Abstract Number: 1324 • ACR Convergence 2025
Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study
Maartje Cox¹, Kyra Theunissen², Kenneth Meijer², Annick Timmermans³, Sofia Ramiro⁴, Annelies Boonen⁵ and Guy Plasqui², ¹Australian National Phenome Centre - Murdoch University, Booragoon, Western Australia, Australia, ²Maastricht University, Maastricht, Netherlands, ³Universiteit Hasselt, Hasselt, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: People with rheumatoid arthritis (pwRA) are prone to fall short of the World Health Organization’s physical activity (PA) recommendations due to perceived fatigue and…
Abstract Number: 1262 • ACR Convergence 2025
Perspectives of Lupus Patients on Quality of Life Measures: A Qualitative Study
Cristina Arriens¹, Fredonna Carthen², Alexandre Cammarata-Mouchtouris¹, Judith James¹, Joan Merrill³ and Motolani Ogunsanya⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Lupus has profound impact on physical, social, and emotional well-being. Health-related quality of life (HRQOL) measures are increasingly incorporated into lupus research and the…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…
Abstract Number: 1149 • ACR Convergence 2025
Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
Aleksander Lenert¹, Robyn Domsic², Jenna Thomason³, Melanie smith⁴, Petar Lenert⁵, Yongdong (Dan) Zhao⁶, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon⁷ and Polly Ferguson⁸, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Washington, Seattle, WA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵University of Iowa Hospitals and Clinics, Iowa City, IA, ⁶Seattle Children’s Research Institute, Redmond, WA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁸University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Patient symptoms are important in the assessment of disease activity. The Patient Acceptable Symptom State (PASS) is defined as the minimum symptom score beyond…
Abstract Number: 2557 • ACR Convergence 2025
Relationship Between Sleep Quality and Psychiatric Symptoms in Autoimmune Rheumatic Diseases
Karen Yaresi Ramos-Reza¹, Maria Eugenia Corral-Trujillo², Eva Abigaid Galindo-Calvillo¹, Joselyn Aracely Alvarez Meza¹, Fatima Adriana Marin.Muñoz¹, Santiago S. Heredia-Gonzalez¹, Laura Patricia Gallegos-Gloria¹, Norberto Luna-Mireles¹, Estefania Escamilla-Barrientos¹, Alicia Abigail Treviño-Arreola¹, Fatima Humphrey-Escamilla¹, Jesus Alberto Cardenas-de la Garza³, Miguel Villarreal-Alarcón⁴, Ivan de Jesús Hernandez-Galarza¹ and Dionicio A. Galarza-Delgado⁵, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁴Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁵Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Autoimmune Rheumatic Diseases (ARDs) commonly present with psychiatric symptoms such as chronic fatigue, depression, and anxiety, and often linked to poor sleep quality. Prolonged…
Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Ioannis Parodis¹, Caroline Gordon², Joan Merrill³, Matthias Schneider⁴, Zahi Touma⁵, Teri Jimenez⁶, Thomas Morel⁷, Mina Nejati⁸, Christian Stach⁹, Christine de La Loge¹⁰ and Laurent arnaud¹¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶UCB, Raleigh, NC, ⁷UCB, Basel, Switzerland, ⁸Biogen, Cambridge, MA, ⁹UCB, Monheim am Rhein, Germany, ¹⁰UCB, Brussels, Belgium, ¹¹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…
Abstract Number: 2536 • ACR Convergence 2025
High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area
Mateus Augusto Rangel Nunes, Carlos Teixeira, Laurie Kumano, Gabriela Gutierrez, Vitor Grotti, Ana Paula Toledo Del Rio, Ibsen Coimbra, Alisson Pugliesi and Zoraida Sachetto, UNICAMP, Campinas, Brazil
Background/Purpose: Behçet's disease (BD) is a chronic systemic inflammatory disease classified as a variable vessel vasculitis of unknown etiology. It is marked by recurrent oral…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: 2437 • ACR Convergence 2025
Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Aaron Smith¹, Thuyvan Phan², Leah Luizza³, Anthony Trujillo³, Becki Cleveland¹, Shruti Saxena Beem⁴, Tessa Englund⁵, Claire Timon⁴ and Saira Sheikh⁵, ¹University of North Carolina, Chapel Hill, NC, ²UNC Health, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, ⁴University of North Carolina at Chapel Hill, Chapel Hill, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease with heterogenous presentation. Most patients with SLE report fatigue or brain fog, which often…
Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Rosa Maria Morlà Novell¹, Beatriz Frade Sosa², Maria López-Lasanta³, Meritxell Sallés Lizarzáburu⁴, Noemí Busquets Pérez⁵, Georgina Salvador Alarcón⁶, Marta Valls Roc⁷, Virginia Ruiz-Esquide⁸, Lola Tobalina Mastre⁹, Raimon Sanmartí⁸ and José Gomez-Puerta¹⁰, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁴Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁷Hospital Universitari Dr Trueta, Girona, Sudan, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
Abstract Number: 2429 • ACR Convergence 2025
mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Shanthini Kasturi¹, Erin Morrissey¹, Anna Deck², Nina Gulati², Zoe Gilbard², Kiran Singh¹, Monique Gore-Massy³, Faye Chiu⁴, Priscilla Calvache⁵, Jillian Rose-Smith⁵, Andre Ogura⁶, Lucas Ogura Dantas⁶, Wambui Machua⁷, Julia Nguyen⁸, Lisa Mandl⁵, Hocine Tighiouart¹, Ludovic Trinquart², Iris Navarro-Millan⁹ and Sara Folta¹⁰, ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³N/A, West Orange, NJ, ⁴N/A, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Ambulomics, Arlington, MA, ⁷Piedmont Healthcare, Atlanta, GA, ⁸Hospital for Special Surgery, New York, ⁹Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ¹⁰Tufts Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is a highly prevalent and debilitating symptom affecting up to 90% of individuals living with systemic lupus erythematosus (SLE). Despite its significant impact,…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].